Apeloa Pharmaceutical Co

Apeloa Pharmaceutical Co ROA

The Return on Assets (ROA) of Apeloa Pharmaceutical Co (000739.SZ) as of Oct 22, 2026 is 7.23 %. In the previous year, Return on Assets (ROA) was 8.10 % — a change of -10.74% (lower).

ROA

7.23 %

YoY

-10.74%

Last updated:

In 2025, Apeloa Pharmaceutical Co's return on assets (ROA) was 7.23 %, a -10.74% increase from the 8.10 % ROA in the previous year.

The Apeloa Pharmaceutical Co ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
6.44 CNY
Jan 1, 2019
8.48 CNY
Jan 1, 2020
10.90 CNY
Jan 1, 2021
10.56 CNY
Jan 1, 2022
8.23 CNY
Jan 1, 2023
8.27 CNY
Jan 1, 2024
8.10 CNY
Jan 1, 2025
7.23 CNY
The Apeloa Pharmaceutical Co ROA history
YEARROAYoY
7.23 %-10.74%
8.10 %-2.00%
8.27 %+0.45%
8.23 %-22.11%
10.56 %-3.05%
10.90 %+28.44%
8.48 %+31.69%
6.44 %+42.89%
4.51 %-3.64%
4.68 %+21.22%
3.86 %-39.36%
6.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Apeloa Pharmaceutical Co Stock analysis

What does Apeloa Pharmaceutical Co do? Apeloa Pharmaceutical Co., Ltd. generates revenue through the research, development, and production of active pharmaceutical ingredient (API) intermediates, contract development and production services (CDMO), and preparations. The company’s main products include bulk drugs, intermediates, chemical preparations, and Chinese traditional medicine preparations such as ubenimex capsules, cefixime, and amantadine. These products are sold to both domestic and overseas markets, with the company distributing its offerings across these segments. The firm’s business model focuses on serving pharmaceutical manufacturers and healthcare providers through its comprehensive range of API intermediates and finished preparations. The company’s revenue streams are derived from the sale of bulk drugs, intermediates, and chemical preparations, alongside its Chinese traditional medicine preparations like ubenimex capsules and cefixime. These products are targeted at pharmaceutical manufacturers seeking API intermediates and finished drug formulations. Apeloa Pharmaceutical serves both domestic and international clients, with its products distributed in both markets. The company’s CDMO services further support clients in the development and production of pharmaceutical products. Apeloa Pharmaceutical’s core business involves the production and sale of API intermediates, bulk drugs, and various preparations, including traditional Chinese medicine products. The company’s main customers are pharmaceutical manufacturers and healthcare providers who require intermediates for drug manufacturing and finished preparations for market distribution. Its domestic and overseas market presence ensures a diversified revenue base, with products like ubenimex capsules and amantadine contributing to its product portfolio. Apeloa Pharmaceutical Co is one of the most popular companies on Eulerpool.

ROA Details

Understanding Apeloa Pharmaceutical Co's Return on Assets (ROA)

Apeloa Pharmaceutical Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Apeloa Pharmaceutical Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Apeloa Pharmaceutical Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Apeloa Pharmaceutical Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Apeloa Pharmaceutical Co stock

Return on Assets (ROA) of Apeloa Pharmaceutical Co is 7.23 % in 2025.

Return on Assets (ROA) of Apeloa Pharmaceutical Co changed from 8.10 % to 7.23 %, representing a -10.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Apeloa Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Apeloa Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Apeloa Pharmaceutical Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Apeloa Pharmaceutical Co